About Satiogen
Satiogen is a Healthcare company based in San Diego (United States) founded in 2007 by Andrew Young and Bronislava Gedulin, and was acquired by Mirum Pharmaceuticals in May 2022. Specialty pharma company focused on developing treatment for diabetes. Satiogen has raised $700 thousand across 1 funding round from investors including Mirum Pharmaceuticals and Mesa Verde Venture Partners. Its chief executive, as recorded, is Dan Wood. Its focus areas include Life Sciences, Diabetes and Drugs. Its competitors include Kriya Therapeutics, Sana Biotechnology and Semma Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Satiogen Pharmaceuticals has discovered a metabolic mechanism of action termed the bile acid brake that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. Preclinical experiments testing several drugable concepts have demonstrated metabolic effects comparable to marketed drugs, and a clinical study has extended these findings to humans. Preclinical experiments are also underway with a non-surgical device designed to replicate the benefits of gastric bypass surgery.
- Headquarters San Diego, United States
- Founders Andrew Young, Bronislava Gedulin
- Stage Acquired
- SectorsHealthcare
- Website satiogen.com
- Social LinkedIn
- Acquired by Mirum Pharmaceuticals (May 2022)
- Total Equity Funding$700K (USD)
in 1 rounds
- Latest Funding Round$700K (USD), Series A
Apr 2008
- InvestorsMirum Pharmaceuticals
& 1 more
- Acquired byMirum Pharmaceuticals
(May 2022)
Funding Insights of Satiogen
Satiogen has successfully raised a total of $700K through 1 strategic funding round. The most recent funding activity was a Series A round of $700 thousand completed in April 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $700,000
- Total Rounds 1
- Last Round Series A β $700,000
- First Round $700,000
(Apr 2008)
- Investors Count 1
All 1 funding rounds of Satiogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2008 | $700,000 | Series A | β | β |
2 investors in total: 2 institutional.
Investors in Satiogen
Satiogen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Mirum Pharmaceuticals and Mesa Verde Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| mesaverdevp.com | ||||
Small molecule therapeutics are developed for rare diseases treatment. | 2018 | mirumpharma.com | Menlo Park, United States |
Investor details for Satiogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Satiogen
3 people are tracked at Satiogen (3 in leadership).
| Name | Role | Group |
|---|---|---|
Andrew Young | Co-Founder | Leadership |
Bronislava Gedulin | Co-Founder | Leadership |
Dan Wood | CEO | Leadership |
Complete people profiles for Satiogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Satiogen
3 dated milestones of Satiogen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Satiogen is founded.
- Funding First funding round of $700K.
- Exit Acquired by Mirum Pharmaceuticals.
Competitors of Satiogen
Satiogen has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and Semma Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment |
Detailed competitors of Satiogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Satiogen (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Satiogen
Complete news archive for Satiogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Satiogen
Satiogen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Satiogen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Dan Wood is the CEO of Satiogen, as recorded in our data.
Satiogen is a funded company, having raised a total of $700K across 1 funding round to date. The company's 1st funding round was a Series A of $700K, raised on Apr 2008.
Satiogen Pharmaceuticals has discovered a metabolic mechanism of action termed the bile acid brake that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. Preclinical experiments testing several drugable concepts have demonstrated metabolic effects comparable to marketed drugs, and a clinical study has extended these findings to humans. Preclinical experiments are also underway with a non-surgical device designed to replicate the benefits of gastric bypass surgery.
Satiogen's top competitors include Sana Biotechnology, Semma Therapeutics and Kriya Therapeutics.
Satiogen has 2 investors. Key investors include Mirum Pharmaceuticals, and Mesa Verde Venture Partners.
Yes. Satiogen was acquired by Mirum Pharmaceuticals in May 2022.

